Virtu Financial Inc. Class A Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Virtu Financial Inc. Class A Common Stock trades at $57.18 (market cap $5.10B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Virtu Financial Inc. Class A Common Stock pays a 1.66% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Virtu Financial Inc. Class A Common Stock for 1 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VIRT | XBI | |
|---|---|---|
Market Cap | $5.10B | $10.11B |
Volume | 871,626 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $67.93 | $169.55 |
52-Week Low | $32.53 | $104.99 |
Typical Hold Time | 1 Days | 38 Days |
Enterprise Value | $14.81B | — |
Dividend Yield | 1.66% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Trailing returns across standard periods
Virtu Financial provides technology-enabled market-making and execution services. Its platforms help institutional, retail, and other market participants trade across global financial markets.
Read more on VIRT →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →